



Living Cell Technologies Limited
 PO Box 3014, Auburn VIC 3123
 ABN: 14 104 028 042

Living Cell Technologies Featured on ABCTV Program, 7.30 Report

New Zealand, Australia, Wednesday, 29 August 2007: World leading xeno cell therapy company, Living Cell Technologies (ASX:LCT; US OTC: LVCLY) announced today that it will be featured on the ABC television network current affairs program, The 7.30 Report at 7.30 pm Wednesday 29 August 2007.

The program explores Living Cell Technologies' (Living Cell) cutting edge therapeutic approach to type I diabetes which involves implanting LCT's proprietary DiabeCell® (insulin-producing pig cells inside a protective seaweed-based coating) into patients with type I diabetes. The program highlights the New Zealand Government's pending approval for LCT's clinical trials of DiabeCell® in New Zealand.

Key interviews in the program include; Professor Bob Elliot, Medical Director, Living Cell and inventor of DiabeCell®, Dr Paul Tan, Chief Executive Officer, Living Cell, Michael Helyer, one of the first diabetes patients to be implanted with the Company's pig cells ten years ago and Dr Stewart Jessamine from Medsafe, New Zealand Government's scientific regulatory body.

A video copy of the program can be downloaded and the transcript can be viewed on-line at; <http://www.abc.net.au/7.30/>

| | | |
|--|---|--|
| Further information: | | |
| Dr Paul Tan CEO, LCT Mobile: +61 402 716 984 | Paris Brooke General Manager, LCT Mobile: +61 407 715 574 | Dr Daniella Goldberg Media & Investor Relations Tel: +61 416 211 067 |

About Living Cell Technologies: www.lctglobal.com

Living Cell is developing live cell therapy products to treat life threatening human diseases. The company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The company entered clinical trials for its diabetes product in 2007. For the treatment of Huntington's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. Living Cell's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. Living Cell also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any



assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of 1 August 2007 and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.